AstraZeneca (AZN) Stock: Tozorakimab Achieves Phase III COPD Success in MIRANDA Study

TLDR Tozorakimab achieved its primary goal in AstraZeneca’s Phase III MIRANDA study for chronic obstructive pulmonary disease The investigational therapy demonstrated significant reduction in moderate-to-severe exacerbations compared to placebo in former and active smokers Study participants received 300mg doses of tozorakimab bi-weekly alongside their standard treatment regimen The positive outcome builds on successful Phase III data from the OBERON and TITANIA studies released in March Regulatory submission is planned with full data presentation scheduled for an upcoming scientific conference AstraZeneca has achieved another clinical milestone with tozorakimab, its investigational chronic obstructive pulmonary disease therapy, as the drug successfully met its primary objective in a third Phase III study. AstraZeneca PLC, AZN Results from the MIRANDA study revealed that tozorakimab achieved a statistically meaningful decrease in the yearly rate of moderate-to-severe COPD exacerbations when compared against placebo. Importantly, these benefits were observed consistently across both the primary cohort of former smokers and the expanded patient group that included individuals who continue to smoke. Study participants administered themselves either tozorakimab 300mg or placebo bi-weekly while maintaining their current standard-of-care medications. The trial specifically recruited individuals who continued experiencing exacerbations despite ongoing treatment with inhaled therapies. The drug’s safety characteristics aligned with previous clinical studies, and investigators reported that tozorakimab was generally well accepted by patients. Building on Earlier Phase III Successes MIRANDA represents the third positive Phase III readout for tozorakimab. Earlier this year in March, AstraZeneca revealed favorable outcomes from two additional Phase III studies — OBERON and TITANIA — which evaluated the medication using a monthly administration schedule. By contrast, MIRANDA ...